Intellectual Property India Publishes Patent Application for 'Anti-Dll3 Antibody, And Antibody-Drug Conjugate And Pharmaceutical Use Thereof' Filed by Suzhou Suncadia Biopharmaceuticals Co. Ltd.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Hengrui Pharmaceutical Co. Ltd.

MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202527079421 A) filed by Suzhou Suncadia Biopharmaceuticals Co. Ltd.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu, China, on Aug. 21, for 'anti-dll3 antibody, and antibody-drug conjugate and pharmaceutical use thereof.'

Inventor(s) include Ye, Xin; Yao, Qingqing; and He, Feng.

The application for the patent was published on Sept. 12, under issue no. 37/2025.

According to the abstract released by the Intellectual Property India: "Provided are an anti-DLL3 antibody, and an antibody-drug conjugate and pharmaceutical use thereof. The present invention specifically relates to an anti-DLL3 antibody-exatecan drug conjugate represented by general formula Pc-L-Y-D, wherein Pc is an anti-DLL3 antibody, and L, Y and n are as defined in the description."

The patent application was internationally filed on Feb. 27, 2024, under International application No.PCT/CN2024/078818.

Disclaimer: Curated by HT Syndication.